Discussing GMV with another investor recently they expressed some concerns re. the HKSE listing raising the required capital. Fair question. I'm hardly the best person to answer this question, maybe one of our GMVers would like to comment?
Below is some info surrounding the info taken from the announcement 8th August 2018.
Apologies if this topic has appeared earlier in this thread.
Cheers
Mazer
======================================= From GMV announcement: The management of G Medical have appointed global Investment Bank, UOB Kay Hian (Hong Kong) Limited (UOB to act as the financial adviser.
UOB Founded by Datuk Wee Kheng Chiang, UOB was incorporated on 6 August 1935 as the United Chinese Bank; the change of name was effected in 1965. The Bank catered mainly to the Fujian community in its early years but over the past decades, UOB has grown in strength and stature. Through a series of acquisitions, it is now a leading bank in Asia. Besides Far Eastern Bank in Singapore, UOB’s major banking subsidiaries in the region are United Overseas Bank (Malaysia), United Overseas Bank (Thailand), PT Bank UOB Indonesia and United Overseas Bank (China). Today, the UOB Group has a network of more than 500 offices in 19 countries and territories in Asia Pacific, Western Europe and North America. https://www.uob.com.sg/uobgroup/about/story/our-corporate-profile.page
From GMV ann: "... G Medical cautions investors that there can be no certainty that the proposed IPO will proceed and that the listing is subject to satisfaction of all legal and regulatory requirements in Australia and Hong Kong,..."
HKSE integrity [good for GMV?] Alibaba held its record $25 billion public float in New York in 2014 after Hong Kong, its favoured venue, refused to accept its governance structure where a self-selecting group of senior managers control the majority of board appointments. https://www.cnbc.com/2018/01/09/ali...nsider-hong-kong-listing-says-founder-ma.html
HKSE IPO's 2018 will be a "very strong year" for IPOs in the city, according to JPMorgan's Gu. More financial technology, consumer and health-care companies will come to market next year, said Mille Cheng, co-head of Asia Pacific equity capital markets at Morgan Stanley.
"Hong Kong’s stock exchange has set a goal of overtaking New York’s Nasdaq within five years in terms of the number of listings of mainland Chinese biotechnology companies and their market capitalisation, according to HKEX chief executive Charles Li Xiaojia.
The declining trend came after funds raised at IPO in Hong Kong in 2017 fell 45% to US$13.87 billion, the lowest level since 2012, according to Thomson Reuters data.
A lack of big tech-related stocks and other blockbuster capital raising are among the reasons Hong Kong lost its global IPO market crown – a title it retained in 2015 and 2016. In 2017, the city slid to the No 3 spot globally for IPOs, overtaken by New York and Shanghai." https://www.scmp.com/business/compa...third-globally-ipos-q1-funds-raised-fell-26pc
Cayman Islands address explained? "Other than companies incorporated in Hong Kong, the HKSE has, as of May 2018, recognised companies incorporated in the People’s Republic of China (PRC), the Cayman Islands and Bermuda as ‘eligible’ for listing. The relevant listing applicant incorporated in any of these jurisdictions is not required to make specific submissions to seek the HKSE’s approval insofar as jurisdiction of incorporation is concerned ." https://gettingthedealthrough.com/area/78/jurisdiction/40/initial-public-offerings-2019-hong-kong/
GMV Ann: Under the terms of the Agreement, UOB will obtain an in-principle approval from the Hong Kong Stock Exchange to proceed with the listing application, with the initial market capitalisation of GYIMSTC Ltd to be at least HK$1,500,000,000 (~A$260 million), as required under the Hong Kong Stock Exchange Listing Rules for biotech companies (Chapter 18A provisions). http://en-rules.hkex.com.hk/en/display/display_main.html?rbid=4476&element_id=5193
to act as the financial adviser.
